Armata Pharmaceuticals Inc. (NYSE American: ARMP) experienced a 7.7% increase in premarket trading on Tuesday after the company announced it had secured an extra $2.5 million in non-dilutive funding from the U.S. Department of Defense. This most recent allocation enlarges the cumulative DoD award to $28.7 million.
The funding was routed through the Medical Technology Enterprise Consortium (MTEC) and is being managed by the Naval Medical Research Command - Naval Advanced Medical Development. The award is funded by the Defense Health Agency and the Joint Warfighter Medical Research Program.
The DoD support is earmarked for advancing AP-SA02, Armata's lead clinical candidate. AP-SA02 is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia (SAB) resulting from either methicillin-sensitive S. aureus (MSSA) or methicillin-resistant S. aureus (MRSA). The newly announced $2.5 million specifically targets activities intended to support Phase 3 readiness for AP-SA02.
Armata is a late clinical-stage biotechnology company focused on developing bacteriophage therapeutics to treat antibiotic-resistant and otherwise difficult-to-treat bacterial infections. The company is moving forward with plans to initiate a randomized Phase 3 superiority study of intravenous AP-SA02 in complicated SAB in the second half of 2026.
Regulatory designations for AP-SA02 include both Qualified Infectious Disease Product (QIDP) and Fast Track status from the U.S. Food and Drug Administration, as noted by the company. These designations were referenced in the company's statements regarding the program.
Context and significance
The additional non-dilutive award extends existing DoD investment in Armata's development program and is targeted at advancing the candidate toward Phase 3 readiness. The funding pathway and managing organizations are explicitly tied to military medical research structures and defense health funding priorities.
What remains unchanged
No new timelines or changes to the planned Phase 3 start window in the second half of 2026 were announced beyond confirmation that the $2.5 million will fund Phase 3 readiness activities.